Skip to content

MOTS-c

PeptidespeptideEarly stage

Availability Not yet prescribable · sold for research use only

What it is

MOTS-c is a sixteen amino acid peptide encoded inside mitochondrial DNA rather than in the cell nucleus, reported in 2015. That origin is the interesting part: mitochondria appear to send signals to the rest of the cell, and MOTS-c is one of the first of those messages to be identified and named.

Why people take it

It is marketed as the exercise-mimetic peptide, on the strength of animal work where it improved insulin sensitivity and metabolic flexibility, and on human observations that circulating levels rise with exercise and fall with age. People buy it wanting the metabolic side of training, better glucose handling and energy, from an injection.

How it's delivered

Some clinics market subcutaneous injections. MOTS-c is not on FDA's compounding list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound MOTS-c acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing MOTS-c; its Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. Outsourcing facilities (503B) are outside it. No human treatment trial has established safety or efficacy for native MOTS-c. There is no established human dose, because no dosing trial of MOTS-c itself has been published.

Where the evidence stands

The discovery paper is real science and the human record is nearly empty. In mice, MOTS-c improved insulin sensitivity and reduced diet-induced obesity, and human observational work links higher levels to better metabolic markers and to exercise. But no trial has ever given MOTS-c to people and measured an outcome. The closest attempt was a company's MOTS-c analog, CB4211, which completed an early-phase study in obesity and fatty liver with modest signals before the company wound down. MOTS-c was removed from Category 2 following withdrawal of its nomination in April 2026, and FDA continues to identify potential significant safety risks.

Estimated cost

  • No approved product and no verified reference price
  • Not covered by insurance

Who offers it

We don't list providers for MOTS-c. There is no approved product, and we haven't verified any provider against the conditions of HHS's draft October 2026 interim compounding policy. Anything sold online as a research chemical is outside that policy.

Go deeper

The compound page, MOTS-c in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Sleep, Recovery, and Energy, covers the mitochondrial peptide group and how to read an exercise-mimetic claim.

Longevity.io is for educational purposes only and is not medical advice. A peptide that rises with exercise is not evidence that injecting it substitutes for exercise. Confirm eligibility, product source, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint